Kymera Therapeutics, INC 8-K filings

Kymera Therapeutics reports the resignation of a director, appointment of a new audit committee member, and shareholder approval of an amendment to their stock option plan.

Kymera Therapeutics announced its first quarter 2024 financial results, highlighted by a strong cash position and progress in its clinical pipeline, particularly in immunology.

Kymera Therapeutics has appointed Felix J. Baker, Ph.D., as a new independent director and Lead Independent Director, effective March 28, 2024.

Kymera Therapeutics announced its fourth quarter and full year 2023 financial results, along with updates on its clinical pipeline, highlighting progress in multiple programs and a strong cash position.